Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Expansion Outlook: What Revenue Opportunities Lie Ahead?
The market for chronic inflammatory demyelinating polyneuropathy (CIDP) has experienced robust expansion lately. Projections indicate that this market will expand from $2.27 billion in 2025 to a total of $2.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors fueling this growth during the preceding period include heightened awareness surrounding rare autoimmune nerve disorders, enhanced accessibility of intravenous immunoglobulin (IVIg) treatments, progress in electrodiagnostic assessment methods, a greater concentration of specialized neurological care, and improved identification of distinct CIDP classifications.
The global market for chronic inflammatory demyelinating polyneuropathy (CIDP) is poised for substantial expansion, projected to reach $3.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth over the forecast period is propelled by several key factors, including advancements in targeted immunotherapies, a heightened emphasis on reducing adverse treatment effects, the proliferation of remote patient monitoring capabilities, escalating demand for therapies that achieve sustained remission, and augmented investments in rare disease research. Notable trends anticipated within this timeframe involve the growing preference for intravenous immunoglobulin (IVIG) as an initial treatment, the increasing implementation of individualized treatment plans, the broader incorporation of sophisticated diagnostic technologies, the expansion of care models delivered at home, and a more dedicated approach to long-term management of the condition.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Industry Drivers: What Is Driving Revenue Growth?
Advancements in healthcare spending are anticipated to be a key catalyst for the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. This surge in medical expenditure stems from heightened investments in healthcare facilities, a growing need for sophisticated therapies, broader health insurance accessibility, and governmental initiatives aimed at improving healthcare reach. Elevated spending on health services facilitates access to cutting-edge treatments, enables earlier detection, and promotes more effective management of CIDP, ultimately leading to improved patient prognoses and an enhanced quality of life. Illustratively, the UK’s Office for National Statistics reported in May 2024 that overall healthcare spending experienced a nominal rise of 5.6% between 2022 and 2023, a notable acceleration from the 0.9% growth recorded in the preceding year. Consequently, increasing healthcare expenditure is identified as a primary driver for the uplift in the CIDP market.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Analysis: What Are The Major Market Categories?
The chronic inflammatory demyelinating polyneuropathy (cidp) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administrations
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
#Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Trends: What Is Influencing The Future Outlook?
Key players within the chronic inflammatory demyelinating polyneuropathy (CIDP) sector are prioritizing the development of innovative treatments like intravenous immunoglobulin (IVIG) therapy, with the aim of boosting treatment effectiveness, refining patient results, and delivering more precise and effective immune system regulation for managing this condition. IVIG therapy functions by administering purified antibodies sourced from healthy donors, a process designed to help regulate the body’s immune responses and mitigate inflammation associated with autoimmune disorders. As an illustration, in January 2024, Takeda Pharmaceutical Company Limited, a biopharmaceutical firm based in Japan, revealed that the FDA had granted approval for GAMMAGARD LIQUID for use as an intravenous immunoglobulin (IVIG) treatment for adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). This regulatory milestone permits its application as initial or “induction” therapy, commencing with a specified initial dosage, and subsequently transitioning to maintenance doses to facilitate ongoing disease management and enhance the function of the nervous system and muscles.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Leading Companies Driving Competitive Growth
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Hualan Biological Engineering Inc, argenx SE, Bio Products Laboratory Ltd., Kedrion S.p.A, Biotest AG, Hansa Biopharma AB, UCB SA, Teva Pharmaceutical Industries Ltd, Merck & Co Inc, Roche Holding AG, Biogen Inc, Momenta Pharmaceuticals, Teijin Pharma Limited, Sanquin Plasma Products BV, Fresenius Kabi AG, Immunovant Sciences GmbH, Akari Therapeutics Plc, GeNeuro Pharmaceuticals, MedDay Pharmaceuticals, HanAll Pharma
Access The Complete Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Geographic Distribution And Regional Opportunities
North Americawas the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2025. The regions covered in the chronic inflammatory demyelinating polyneuropathy (cidp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
